| Cash Flow | 2025-09-30 |
|---|---|
| Net cash used in investing activities | 0 |
| Effects of exchange rates on cash | 0 |
| Change in inventory reserve | 0 |
| Loss on deconsolidation of subsidiaries | 0 |
| Change in fair value of eib loan guaranty | 0 |
| Gain on impairment adjustment | 0 |
| Gain on settlement of compensation expenses | 0 |
| Inventory | 0 |
| Deferred revenue | 0 |
| Net income | 2,493,129 |
| Depreciation and amortization | 141,043 |
| Accounts receivable | 4,014,580 |
| Prepaid expenses and other current assets | -244,269 |
| Deferred offering costs | 6,269 |
| Intangible assets | 50,000 |
| Accounts payable | 62,580 |
| Accrued compensation and benefits | -37,463 |
| Accrued liabilities | 19,681 |
| Operating lease liabilities | -127,821 |
| Stock compensation expense | 284,208 |
| Net cash used in operating activities | -978,685 |
| Proceeds from issuance of preferred stock, net of issuance costs | 0 |
| Payments on finance lease obligations | 0 |
| Proceeds from short term insurance financing | 284,304 |
| Payments on short term insurance financing | 202,061 |
| Net cash provided by financing activities | 82,243 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -896,442 |
| Cash and cash equivalents at beginning of period | 1,612,915 |
| Cash and cash equivalents at end of period | 716,473 |
OPGEN INC (OPGN)
OPGEN INC (OPGN)